0001209191-21-034718.txt : 20210520 0001209191-21-034718.hdr.sgml : 20210520 20210520205009 ACCESSION NUMBER: 0001209191-21-034718 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210518 FILED AS OF DATE: 20210520 DATE AS OF CHANGE: 20210520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Xie Jian CENTRAL INDEX KEY: 0001819718 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37894 FILM NUMBER: 21946325 MAIL ADDRESS: STREET 1: C/O FULGENT GENETICS, INC. STREET 2: 4978 SANTA ANITA AVE., SUITE 205 CITY: TEMPLE CITY STATE: CA ZIP: 91780 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulgent Genetics, Inc. CENTRAL INDEX KEY: 0001674930 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 812621304 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205 CITY: TEMPLE CITY STATE: CA ZIP: 91780 BUSINESS PHONE: 626-350-0537 MAIL ADDRESS: STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205 CITY: TEMPLE CITY STATE: CA ZIP: 91780 FORMER COMPANY: FORMER CONFORMED NAME: Fulgent Diagnostics, Inc. DATE OF NAME CHANGE: 20160517 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-18 0 0001674930 Fulgent Genetics, Inc. FLGT 0001819718 Xie Jian C/O FULGENT GENETICS, INC. 4978 SANTA ANITA AVE., STE 205 TEMPLE CITY CA 91780 0 1 0 0 Chief Operating Officer Common Stock 2021-05-18 4 S 0 931 70.7102 D 341041 D Common Stock 2021-05-20 4 S 0 1000 74.48 D 340041 D The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. The shares were sold in multiple transactions at prices ranging from $69.61 to $71.05, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. /s/ Paul Kim as Attorney-in-Fact 2021-05-20